Passage BIO, Inc. (PASG) Form 8-K — Nov 18, 2026
Passage Bio received a Nasdaq deficiency letter on November 12, 2026 for failing Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders' equity. The company reported just $50,000 in stockholders' equity in its Q3 2026 10-Q and did not meet alternative compliance standards. The deficiency has no immediate effect on listing. Passage Bio expects to cure it by completing its previously announced mergers with Remix Therapeutics, after which the combined company will rename to Remix Therapeutics and trade as RMTX.
Key figures
- Reported stockholders equity
- 50000
- Minimum stockholders equity requirement
- 2500000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.